Wegovy is FDA-approved for promoting weight loss in adults with obesity (BMI 30 kg/m or more) and overweight (BMI 27 kg/m or more) with at least one health condition associated with increased body weight such as high blood pressure (hypertension), high cholesterol levels, heart diseases, and type 2 diabetes in patients aged 12 or more, when combined with exercise and dietary modifications
[12] Cheng, J.-R., Zheng, J., Li, Y., Shi, H., Yang, N., Lei, Y., Wan, Y.-F
The program assists patients with these authorizations by providing accurate, medically detailed information that reflects true clinical need
At 2.5 mg weekly, participants experienced an average weight loss of 35% of their starting body weight within the first 48 weeks
Retatrutide (LY3437943 40 mg) GLP-1 + GIP + Eli Lilly
Many patients find that this method helps them finally break through weight loss plateaus and achieve lasting changes